Post hoc analysis of DELIVER: among participants with migraine and 2-4 failed preventives who had a ≥50% response in weeks 1-12 on eptinezumab, 61.0% (100 mg) and 73.8% (300 mg) kept that response across the full 72 weeks.
Secondary analysisn = 239
Ailani et al. Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed